Filing Flows › Yarrow Bioscience (YARW) › Q1 2026
Yarrow Bioscience (YARW) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Yarrow Bioscience (YARW) reported revenue of $86K for the first quarter 2026 (Q1 2026), -57% from a year earlier.
Yarrow Bioscience, Q1 2026: revenue $86K (-57% year over year), net loss $3.6M, operating cash flow −$4.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86K | — | -57% |
| Operating profit | −$3.8M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$4.1M | — | — |
What changed
Revenue was $86K in Q1 2026, down 57% year over year.
Operating costs exceeded revenue by $3.8M, an operating margin of -4437.2%. Total costs fell 58% while revenue fell 57%. The quarter ended with a net loss of $3.6M.
Operating cash flow was −$4.1M. Non-cash charges added back $6K of depreciation and $474K of share-based compensation. Working capital and other items used $1.0M.
Questions
What was Yarrow Bioscience's revenue in the first quarter 2026?
Yarrow Bioscience (YARW) reported revenue of $86K for the first quarter 2026 (Q1 2026), -57% from a year earlier.
Source: Yarrow Bioscience 10-Q on SEC EDGAR.